RxDoctor Payments Data

Eva Volf, MD

Dermatology · Swampscott, MANPI 1124311857

Payments from drug & device makers

$2,822in general payments, 2019–2025

Across 114 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$863
  • AbbVie$837
  • Johnson & Johnson$524
  • Galderma Laboratories, L.p.$85
  • Genentech USA, Inc.$73
  • Lilly USA, LLC$71
  • plus $368 from 12 others

What the payments were for

  • Food & beverage$2,46387%
  • Education$35913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,822 in reported general payments places this provider in the 65th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$170,467
Medicare patients
465
Services billed
2,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$359,383
Humira(Cf) PenAdalimumab11$141,497
Dupixent PenDupilumab29$105,714
Humira(Cf)Adalimumab11$79,523
OtezlaApremilast12$54,531
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc95$4,510
Triamcinolone Acetonide179$3,615
Calcipotriene21$2,734
Ketoconazole148$2,615
Fluorouracil34$2,467
Tacrolimus19$2,466
Clobetasol Propionate41$1,813
Tretinoin28$1,705
Fluocinonide62$1,539
Alclometasone Dipropionate27$959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$837$79,52311 claims
AmgenOtezla$20$54,53112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 552 dermatology providers in Massachusetts.

Other dermatology in Swampscott

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →